PhotoBioModulation
And The Brain
PhotoBioModulation And The Brain
Parkinson's Disease
PubMed | PMID: 38276234 PMCID: PMC10819946 DOI: 10.3390/jpm14010112 | 2024
Light Therapy Treatment For Moderated Parkinson's Disease symptoms
★ Key Take-Aways
⮕ Potentially Effective Treatment for a Range of Clinical Signs & Symptoms of PD
⮕ PBM treatment may be one of the few, and perhaps only, treatments for Parkinson’s disease that can be translated from pre-clinical experiments to a clinical effect
Brian Bicknell, Ann Liebert, and Geoffrey Herkes,
Liang Cheng, Academic Editor and Edward J. Modestino, Academic Editor
Parkinson’s disease is the second most common neurodegenerative disease and is increasing in inci‐ dence. The combination of motor and non-motor symptoms makes this a devastating disease for people with Parkinson’s disease and their care givers. Parkinson’s disease is characterised by mitochondrial dysfunction and neuronal death in the substantia nigra, a reduction in dopamine, accumulation of α- synuclein aggregates and neuroinflammation. The microbiome–gut–brain axis is also important in Parkinson’s disease, involved in the spread of inflammation and aggregated α-synuclein. The mainstay of Parkinson’s disease treatment is dopamine replacement therapy, which can reduce some of the motor signs. There is a need for additional treatment options to supplement available medications.
Photobiomodulation (PBM) is a form of light therapy that has been shown to have multiple clinical benefits due to its enhancement of the mitochondrial electron transport chain and the subsequent increase in mito‐chondrial membrane potential and ATP production. PBM also modulates cellular signalling and has been shown to reduce inflammation. Clinically, PBM has been used for decades to improve wound healing, treat pain, reduce swelling and heal deep tissues. Pre-clinical experiments have indicated that PBM has the potential to improve the clinical signs of Parkinson’s disease and to provide neuroprotec‐ tion. This effect is seen whether the PBM is directed to the head of the animal or to other parts of the body (remotely). A small number of clinical trials has given weight to the possibility that using PBM can improve both motor and non-motor clinical signs and symptoms of Parkinson’s disease and may potentially slow its progression.
1. Introduction
Parkinson’s disease is the second most prevalent neurodegenerative disease after Alzheimer’s disease, affecting up to 10 million people worldwide and almost 1 million in the USA alone as of 2017 (https://www.parkinson.org/understanding-parkinsons/statistics; URL accessed on 16 November 2023). Parkinson’s disease is the most rapidly increasing neurodegenerative disease worldwide [1] due a longer disease duration and an increasing incidence with age [2]. It is also possible that the current COVID-19 pandemic could further accelerate the number of Parkinson’s disease cases [3,4], along with a worsen‐ ing of the motor and non-motor signs and symptoms [5]. Parkinson’s disease has a huge social and economic cost, with people with Parkinson’s disease (PwP) living in a state of dependence for many years, at an estimated cost of USD 51.9 billion in 2017, including USD 26.5 billion in care giver, non-medical costs and productivity losses [6]. This is projected to rise to USD 79 billion by 2037.
This review will discuss the current state of Parkinson’s disease diagnosis, pathology, symptoms, treat‐ ment and the microbiome–gut–brain axis (MGBA) and will present an argument for the use of photo‐ biomodulation as an adjunct treatment for the symptoms of Parkinson’s disease.
PhotoBioModulation And Bell's Palsy
An Effective Therapeutic Option for Patients with Bell's Palsy
★ Key Take-Aways ⮕
⮕ A therapy that is painless, comfortable, and without systemic side effects
⮕ Regardless of the age, shortening the recovery time obtained with conventional therapies and avoiding sequelae
João Paulo Colesanti Tanganeli, Simone Saldanha Ignácio de Oliveira, Tamiris da Silva,
Kristianne Porta Santos Fernandes, Lara Jansiski Motta, and Sandra Kalil Bussadori
Idiopathic facial paralysis, also known as Bell's palsy, exerts a negative effect on the quality of life. Although the prognosis is good in the majority of cases, a significant percentage of affected individuals may have sequelae that can negatively affect their lives. The use of therapeutic measures as early as possible can improve the prognosis. This article describes the successful use of laser-photobiomodulation as a single therapy in a patient with Bell's palsy and confirms the possibility of using this therapeutic modality as a good choice, since it is a therapy that is painless, comfortable, and without systemic side effects. The findings demonstrate that the adequate use of laser-photobiomodulation can be an effective therapeutic option for patients with Bell's palsy, regardless of the age, shortening the recovery time obtained with conventional therapies and avoiding sequelae.
Further studies are needed for the establishment of adequate protocols.
PubMed | PMID: 32231809 PMCID: PMC7091526 DOI: 10.1155/2020/9867693